Stories
Slash Boxes
Comments

SoylentNews is people

posted by janrinok on Tuesday August 23 2016, @05:53PM   Printer-friendly
from the patents-are-power dept.

Illumina Inc. and Oxford Nanopore Technologies have reached a settlement in this legal battle, according to a U.S. International Trade Commission document released last week. Oxford has agreed not to import or sell any product containing a pore with an amino acid sequence at least 68% similar to Mycobacterium smegmatis porin (Msp)—the protein at the heart of Illumina's infringement claim—and to destroy any inventory of such products.

[...] Illumina, Inc.—which dominates the genetic sequencing industry—sued Oxford Nanopore Technologies, the first company to market a commercial nanopore platform. Illumina claims that Oxford's two flagship devices infringe on patents that Illumina controls.

[...] Illumina, meanwhile, has yet to release a nanopore platform

[...] Illumina's chance of winning the case might come down to a "very messy" aspect of patent law called the doctrine of equivalents, he says. The doctrine holds that a party can be liable for infringement even if their product doesn't literally match what's described in a patent, provided their product performs the same function, in the same way, to achieve the same result as the patented invention.

https://en.m.wikipedia.org/wiki/Doctrine_of_equivalents
https://www.sciencemag.org/news/2016/03/gene-sequencing-technology-sparks-patent-fight-shrouded-mystery


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 0) by Anonymous Coward on Tuesday August 23 2016, @06:22PM

    by Anonymous Coward on Tuesday August 23 2016, @06:22PM (#392227)

    I think gringer is in Australia or New Zealand, so it might not affect him.